1. Treatment for stroke
JPI-289 is a new synthetic molecule, which demonstrates outstanding benefits for stroke treatment. Jeil has completed phase I study, acquired IND approval, and is recruiting stroke patients for phase 2A clinical trial. JPI-289 showed excellent efficacy in a monkey stroke model.
2. Anti-cancer agentn
JPI-547 is an anti-cancer agent and acts as a dual inhibitor of PARP and tankyrase. Non-clinical study of JPI-547 was completed and the IND for Phase 1 was approved. Phase I clinical trial is in progress.
3. Neuropathic Pain
A drug for neuropathic pain is being developed by TRPV-1 inhibition. This project is sponsored by the Ministry of Science & ICT as a part of biomedical technology development program for 5 years from the year 2016 and research collaboration is being conducted with prof. Ji-Woo Lee at Seoul National University.
4. SGLT1/2 dual inhibitor for type 1 diabetes treatment
JP-2266 is a new synthetic small molecule that controls postprandial hyperglucose by oral administration to improve conditions of type 1 diabetes mellitus and can be used as combination therapy with insulin. JP-2266 is currently under pre-clinical studies.
5. P-CAB (Potassium-Competitive Acid Blocker) for GERD
Jeil has developed a drug for GastroEsophageal Reflux Disease (GERD) treatment having unique mode of action compared to that of proton pump inhibitors (PPIs). Pre-clinical studies were completed and Phase 1 trial is in progress in Korea. Also, this project is sponsored by the Ministry of Health & Welfare for approval of global clinical trial.
6. Stem Cell Therapy for Parkinson's disease and retinal degenerative diseases
Jeil is currently engaged in development of a treatment using embryonic stem cells for Parkinson’s disease and retinal degenerative disease.
7. Autophagy enhancer for type 2 diabetes treatment
Autophagy has an important role in metabolism by controlling hormone action and organelle function and dysregulated autophagy might play a role in the pathogenesis of diabetes. Systemic autophagy insufficiency could be a factor in the progression from obesity to diabetes, and autophagy modulators have therapeutic potential against type 2 diabetes.